GB2262524A - Pharmaceutically active 2-hydroxy-benzylamines - Google Patents
Pharmaceutically active 2-hydroxy-benzylamines Download PDFInfo
- Publication number
- GB2262524A GB2262524A GB9126831A GB9126831A GB2262524A GB 2262524 A GB2262524 A GB 2262524A GB 9126831 A GB9126831 A GB 9126831A GB 9126831 A GB9126831 A GB 9126831A GB 2262524 A GB2262524 A GB 2262524A
- Authority
- GB
- United Kingdom
- Prior art keywords
- alkyl
- treatment
- formula
- hydroxy
- salt form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compounds of the formula <IMAGE> wherein R1, R2 and R3 are the same or different and represent hydrogen, hydroxy, trifluormethyl, alkyl, alkoxy, acyloxy, halogen or benzyloxy, or two of these substituents together with the carbon atoms to which they are attached form an aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, and R4 represents hydrogen or a group of formula <IMAGE> wherein R5 represents hydrogen or alkyl and R6, R7 and R8 are the same or different and represent hydrogen, hydroxy, trifluormethyl, alkyl, alkoxy, acyloxy, halogen or benzyloxy, or two of these substituents together with the carbon atoms to which they are attached form an aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, in free form or, where such forms exist, in acid addition salt form, are useful as PKC-inhibitors in the treatment of inflammatory diseases such as arthritis, in the treatment and prophylaxis of immunological disorders, of allergies, of akin diseases, in transplantations and in the field of oncology.
Description
Organic compounds, processes for their production and their use
The present invention concerns new organic compounds, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals especially as PKCinhibitors in the treatment of inflammatory diseases such as arthritis. in the treatment and prophylaxis of immunological disorders, of allergies, of skin diseases, in transplantations and in the field of oncology.
More particulariy the invention concerns compounds of the formula
wherein R1, R2 and R3 are the same or different and represent hydrogen, hydroxy, trifluormethyl. alkyl, alkoxy, acyloxy, halogen or benzyloxy, or two of these substituents together with the carbon atoms to which they are attached form an aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, and R4 represents hydrogen or a group of formula
wherein RS represents hydrogen or alkyl and R6, R7 and R8 are the same or different and represent hydrogen, hydroxy, trifluormethyl, alkyl, alkoxy, acyloxy. halogen or benzyloxy, or two of these substituents together with the carbon atoms to which they are attached form an aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, in free form or, where such forms exist. in acid addition salt form.
The present invention also provides a process for the production of compounds of formula which comprises reducing a compound of formula
wherein the substituents are as defined above, whereby in this reaction functional groups may be protected by suitable protecting groups. which may be removed subsequent to the reaction in conventional manner, and recovering the compounds thus obtained in free form or in acid addition salt form.
Functional groups may be protected by suitable protecting groups which may be removed subsequent to the reaction in conventional manner. End products can be isolated and purified according to known methods.
Unless otherwise stated alkyl moieties are preferably straight or branched chains having 1 to 12 expecially 1 to 8 carbon atoms. particuiarly 1 to 6 and especially 1 to 4. Any lower alkyl present as or in a substituent is straight or branched-chain and has preferably 1 to 4 especially 1 or 2 carbon atoms. R1, R2 and F3 represent preferably hydrogen or form together with the carbon atoms they are attached an aromatic ring, e.g. phenyl. Rs represents preferably hydrogen or methyl. Re. R7 and R8 represent preferably hydrogen or form together with the carbon atoms they are attached an aromatic ring, e.g. phenyl.
The process of the invention may be performed following standard procedures for the reduction of Schiff bases, preferably with a complex hydride such as NaBH4. It is preferably carried out in an inert solvent, e.g. in a lower alkanol such as methanol, and at room temperature.
The final products can be isolated and purified in conventional manner. Free bases of the compounds of formula I can be converted into salt forms and vice versa. Suitable acid addition salts are the hydrochloride, hydrogen fumarate or naphthalin-1 .5-disulphonate.
The starting compounds of formula Ill can be prepared by reaction of the corresponding amine of formula
with an aldehyde of formula
wherein the substituents are as defined above. This reaction may be carried out in conventional manner, e.g. in an inert solvent such as an aromatic hydrocarbon, e.g. toluene, and at room temperature or elevated temperature, preferably at lightly elevated temperature and in the presence of a water binding agent, e.g. molecuiar sieve. The thus obtained reaction products of formula Ill may be reacted further without isolation or purification to give the end products of formula I.
The amines of formula IV, wherein R4 represents a group of formula 11, can be prepared according to the following reaction scheme:
In this reaction scheme X represents a leaving group, e.g. halogen such as chlorine or a sulfonate, and the substituents are as defined above.
The remaining infermediates are either known or can be prepared analogously to known processes or e.g. as described in the examples.
The compounds of this invention possess advantageous ohemotherapeutical properties and exhibit on local. systemic or oral application a PKC-inhibitory activity. This activity can be shown in the following test:
Protein kinase C inhibitory test: a) Preparation of enzyme
Freshly removed rat brains are washed in ice-cold physiological saline and the remaining procedure carried out at 4 . Brains are homogenised in buffer H (12 ml per brain) in a Potter S glass homogeniser. The homogenate is spun at 12.OOOg 15 minutes. then at 1O0.OOOg 60 minutes. The supernatant is loaded onto a DEAE-sephacel column run on a FPLC system. For two brains, a 20 ml column equilibrated with buffer A is used.After washing with 12O ml buffer A (1 mllmin), a linear gradient from 0 to 100% buffer B (0.3 M NaCI in buffer A) is applied (100 ml, 1 ml/min) and collected in 2 ml fractions. Fractions containing PKC activity appear between 45 to 75% buffer B. Active fractions are desalted on PD-10 columns, pooled and stored in 1 ml aliquots containing 10% added glycerol in liquid nitrogen. Enzyme activity remains stable for at least two months.
Buffer H: Tris buffer pH 7,5 (20 mM); sucrose (250 mM); EGTA (10 mM); EDTA (2 mM); dithiothreitol (2 mM); PMSF (1 mM); leupeptin (10 mg/litre).
Buffer A: Tris buffer pH 7,5 (20 mM); EGTA (2 mM); EDTA (2 mM); dithiothreitol (2 mM); b) Enzyme assay
Assay components Final cone
Enzyme, diluted in 200 mM tris ph 7,5 25 ul/assay, protein conc. approx. 13 llg/ml phosphatidylserine 10 ,ug/ml 1-oieyl-2-acetyl-sn-glycerol 1 llg/ml histone IllS 200 Fg/ml calcium chloride 0,2 mM magnesium chloride 10 mM
ATP 10 uM [P-32] ATP 1 ACi/ml distilled water, to a total assay volume of 250 ul.
The water-soluble components are used as 10-fold concentrated stock solutions. The lipids are prepared from chloroform stock solutions, dried under nitrogen and resuspended in water at 1 O-fold final concentration by sonication (1 ,5 min, microtip, in ice) to form a mixed emulsion (25111/assay). Enzyme, buffer, water, calcium and histone are pre-mixed as a cocktail. ATP and magnesium are pre-mixed as substrate cocktail (25 ul/assay). Test compounds are dissolved in dimethylsulphoxide at 100-fold concentration (2,5 ul/assay).
Assay sequence: 1. Enzyme cocktail
2. Lipids
3. Test compound
4. Pre-incubation 5 min
5. Substrate cocktail
Assays are performed in plastic tubes incubated 5 min at 30 on a shaking waterbath. Assays are stopped by addition of 1 ml ice cold 25% trichloracetic acid pius 10 ul 2% serum albumin and placed in ice. Insoluble material is filtered on Whatman GFlC filter discs (2,5 cm), washed with 10% TCA, dried and counted for radioactivity.
Assays are performed with and without addition of lipids; PKC activity is defined as the difference between these two in terms of incorporation of P-32 into the TCA-insoluble fraction. All assays are in triplicate.
The compounds of the invention may therefore be used as PKC-inhibitors. For this use, the effective dosage will, of course, vary depending on the particular compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results can be obtained when the compounds are administered at a daily dosage of from about 1 to 30 mglkg of animal body weight, given in suitably divided doses two to four times daily. For most large mammals, the total daily dosage is from about 70 to 2000 mg and dosage forms suitable for internal administration comprise about 17.5 to 1000 mg of the compound in admixture with a solid or liquid chemotherapeutical carrier or diluent. The compounds of the invention may be administered in similar manner to known standards for use in such indications.
The invention therefore also concerns a method of treatment of inflammatory diseases such as arthritis. of treatment and prophylaxis of immunological disorders, of allergies, of skin diseases, in transplantations and in the field of oncology, which comprises administering to a subject in need of such treatment an effective amount of a compound of the invention or a chemotherapeutically acceptable acid addition salt thereof as well as compounds of the invention or chemotherapeutically acceptable acid addition saits thereof for use as chemotherapeutic agents especially as PKC-inhibitory agents.
The compounds may be admixed with conventional chemotherapeutically acceptable diluents and carriers, and, optionally, other excipients and administered e.g. orally in such forms as tablets or capsules. The compounds may aiternatively be administered topically (in such conventional forms as ointments or creams), parenterally or intravenously. The concentrations of the active substance will, of course, vary depending on the compound employed. the treatment desired and the nature of the form etc. In general, however, satisfactory results are obtained e.g. in topical application forms at concentrations of from 0.05 to 5, in particular 0.1 to 1 wt.%. Such compositions also form part of the invention.
Preferred in the above mentioned indications is the compound of example 1, e.g. the N-me thyl-N- ( 1 -naphthylmethyl) -4- (2-hydroxybenzylamino) benzyl amine.
The invention also comprises the compounds of the invention for use as pharmaceuticals, especially for use as PKC-inhibitors.
The invention further comprises a method of treatment of comprising administering a therapeutically effective amount of a compound of the invention to a person in need of such a treatment.
In the following examples which illustrate the invention but in no way limit its scope references to temperature are in degrees celsius.
The following abbreviations are used:
DEAE = diethylaminoethyl
FPLC = fast protein liquid chromatography
PKC = protein kinase C
EGTA = ethylenebis (oxyethylenenitrilo) tetraacetic acid
EDTA = ethylene diamino tetraacetic acid
PMSF = phenylmethyl sulfonyl fluoride
ATP = adenosinetriphosphate
Example 1: N-Methyl-N- (1 -naphthylmethyl)-4- (2-hydroxyb6nzylamino) benzyl amine 0 2 g of molecular sieve (4 A) and 0,33 g of salicyl aldehyde are added to a solution of 0,75 g of N-methyl-N-(1-naphthylmethyl)-(4-amino)benzyl amine in 50 ml of toluene and the reaction mixture is stirred at 400 for 3 hours. Then the mixture is filtered, the toluene evaporated and the residue dissolved in 30 ml of methanol.After addition of 0,10 g of NaBH4 the reaction mixture is stirred at room temperature for 15 hours. The reaction mixture is acidified with 1N HCI, then neutralized with 1N NaOH, evaporated and the residue dissolved in ethyl acetate and water. The organic phases are washed with sodium chloride solution, dried over sodium sulfate and evaporated. Purification of the crude product with ether/petroleum benzine and chromatography (hexane/ethyl acetate = 2/1) gives the title compound as colourless crystals.
m.p.: 138-140 .
The following compounds are prepared analogously:
I Ex.: P1 R2 R3 R4 m.p.
Z 2 H H H -CH2. NH. CH2-0 glassy mass O 3 > H H beige, 120-1250 The required starting materials may be obtained as follows:
A) N-Methyl-N-(1-naphthylmethyl)-(4-amino)benzyl amine a) N-Methyl-N-(1-naphthylmethyl)-(4-nitro3benzyl amine
The mixture of 20 g of N-methyl-(1-aminomethyl)naphthaline.hydrochlorid, 16,9 g of 4-nitrobenzyl chloride and 20 g of powdered patassium carbonate in 200 ml of dry dimethylformamide is stirred at room temperature for 48 hours. Then the reaction mixture is poured onto ice water, extracted with ether, the organic phases are washed twice with water and once with saturated sodium chloride solution, dried over sodium sulfate and evaporated.Chromatography of the residue (toluenelethyl acetate = 10/1) gives the title substance as yellow oil.
b) N-Methyl-N-(I -naphthylmethyl)-(4-amino)benzyl amine 4,1 g of hydraziniumhydroxyd and 1,0 g of palladium black are added to a solution of 10,3 g of N-methyl-N-(1-naphthylmethyl)-(4-nitro)benzyl amine in 150 ml of ethanol and the mixture is refluxed for 2 hours. Then the catalyst is filtered off, and the solvent evaporated. Chro matography of the residue (toluene/ethyl acetate = 10/1) gives the title compound as colourless oil.
B) N- (1 -Naphthylmethyl)- (4-amino)benzyl amine
Proceeding analogously as described under A) gives the title substance as colourless oil.
1K-NMR-Spectra Ex. Spectra: 11) 2.18 (s, 3H); 3.53 (s, 2H); 3.92 (s, 2H); 4.40 (s, 2H); 6.77-6.90 (m, 4H);
7.14-7.24 (m, 4H); 7.37-7.52 (m, 4H); 7.75-7.86 (m, 2H); 8.23 (m, 1H).
22) 3.62 (s, 2H); 4.08 (s, 2H); 4.18 (d, J=6Hz, 2H) 5.89 (t, J=6Hz, 1H); 6.54 (d,
J=7,6Hz, 2H); 6.72 (t, J=7,6Hz, 1H); 6.81 (d, J=7,8Hz, 1H); 7.04 (m, 3H); 7.18
(d, J=6,3Hz, 1H); 7.41-7.52 (m, 4H); 7.80 (d, J=7,9Hz, 1H); 7.90 (m, 1H); 8.11
(m, 1H); 9.50 (s, 1H).
31) 4.20 (s, br, 1H); 4.74 (d, J=2,8Hz, 2H); 6.68 (m, 3H); 7.16-7.27 (m, 4H); 7.38 (t, J=7Hz, 1H); 7.61 (d, J=9Hz, 1H); 7.69 (d, J=8Hz, 1H); 7.85 (d, J=8,4Hz, 1H); 9.52
(s, br, 1H).
Aa1) 2.23 (s, 3H); 3.63 (s, 2H); 3.99 (s, 2H); 7.2-7.6 (m, 6H); 7.80-7.90 (m, 2H); 8.16
(m, 2H); 8.30 (m, 1H).
Ab1) 2.16 (s, 3H); 3.50 (s, 2H); 3.60 (br, 2H); 3.88 (s, 2H); 6.65 (m, 2H); 7.16 (m,
2H); 7.38-7.48 (m, 4H); 7.74-7.84 (m, 2H); 8.20 (m, 1H).
Ba1) 3.99 (s, 2H); 4.25 (s, 2H); 7.39-7.57 (m, 6H); 7.74-7.89 (m, 2H); 8.08-8.20 (m,
3H).
1) CDCI3 2) sMSO-d6
Claims (7)
- Ciaims: 1. Compounds of the formulawherein R1, R2 and Rg are the same or different and represent hydrogen, hydroxy, trifluormethyl, alkyl, alkoxy, acyloxy, halogen or benzyloxy, or two of these substituents together with the carbon atoms to which they are attached form an aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, and R4 represents hydrogen or a group of formulawherein R5 represents hydrogen or alkyl and R6, P7 and Ra are the same or different and represent hydrogen, hydroxy, trifluormethyl, alkyl, alkoxy, acyloxy. halogen or benzyloxy, or two of these substituents together with the carbon atoms to which they are attached form an aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, in free form or, where such forms exist, in acid addition salt form.
- 2. Process for the production of compounds of formulawherein R1, R2 and R3 are the same or different and represent hydrogen, hydroxy, trifluormethyl. alkyl, alkoxy, acyioxy, halogen or benzyloxy, or two of these substituents together with the carbon atoms to which they are attached form an aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, and R4 represents hydrogen or a group of formulawherein R5 represents hydrogen or alkyl and R6, R7 and R8 are the same or different and represent hydrogen, hydroxy, trifluormethyl, alkyl, alkoxy, acyloxy, halogen or benzyloxy, or two of these substituents together with the carbon atoms to which they are attached form an aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, in free form or, where such forms exist, in acid addition salt form, which comprises hydrogenating a compound of formulawherein the substituents are as defined above, whereby in this reaction functional groups may be protected by suitable protecting groups. which may be removed subsequent to the reaction in conventional manner, and recovering the compounds thus obtained in free form or in acid addition salt form.
- 3. A pharmaceutical composition comprising a compound according to claim 1 in free form or as appropriate in pharmaceutically acceptable salt form together with a ieast one pharmaceutically acceptable carrier or diluent.
- 4. A process for the preparation of a pharmaceutical composition according to claim 3 comprising mixing the compound with at ieast one pharmaceutically acceptable carrier or diluent.
- 5. A compound according to claim 1 in free form or as appropriate in pharmaceutically acceptable salt form for use as a pharmaceutical.
- 6. A compound according to claim 1 in free form or as appropriate in pharmaceuticaily acceptable salt form for use as PKC-inhibitors in the treatment of inflammatory diseases such as arthritis, in the treatment and prophylaxis of immunological disorders, of allergies, of skin diseases, in transplantations and in the field of oncology.
- 7. A method of treatment of a compound according to claim 1 in free form or as appropriate in pharmaceutically acceptable salt form for use as PKC-inhibitors in the treatment of inflammatory diseases such as arthritis, in the treatment and prophylaxis of immunological disorders, of allergies, of skin diseases, in transplantations and in the field of oncology, comprising admini stering a therapeutically effective amount of a compound according to claim 1 in free form or as appropriate in pharmaceutically acceptable salt form to a subject in need of such treatment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9126831A GB2262524A (en) | 1991-12-18 | 1991-12-18 | Pharmaceutically active 2-hydroxy-benzylamines |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9126831A GB2262524A (en) | 1991-12-18 | 1991-12-18 | Pharmaceutically active 2-hydroxy-benzylamines |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9126831D0 GB9126831D0 (en) | 1992-02-19 |
GB2262524A true GB2262524A (en) | 1993-06-23 |
Family
ID=10706448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9126831A Withdrawn GB2262524A (en) | 1991-12-18 | 1991-12-18 | Pharmaceutically active 2-hydroxy-benzylamines |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2262524A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552066B1 (en) | 1995-09-11 | 2003-04-22 | Thomas R. Sharpe | Protein tyrosine kinase inhibitors for treating osteoarthritis |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1924685A1 (en) * | 1968-05-15 | 1969-12-04 | Ricoh Kk | Diazotype photographic printing material |
FR2393835A1 (en) * | 1977-06-10 | 1979-01-05 | Anvar | POLYPHENYLENE OXIDE FILMS CONTAINING REAGENT GROUPS AND THEIR PREPARATION BY ELECTROCHEMICAL METHODS |
JPS5865775A (en) * | 1981-10-15 | 1983-04-19 | Terumo Corp | Ion contact preventing membrane |
EP0081782A1 (en) * | 1981-12-14 | 1983-06-22 | Merck & Co. Inc. | Hydroxybenzylamino-aryl compounds, process for preparing and pharmaceutical compositions containing the same |
EP0122321A1 (en) * | 1983-04-13 | 1984-10-24 | Merck & Co. Inc. | Hydroxybenzylamino derivatives as anti-inflammatory agents |
EP0150291A1 (en) * | 1983-11-21 | 1985-08-07 | Merck & Co. Inc. | Substituted 5-hydroxy-2,3-dihydrobenzofurans and 6-hydroxy-2,3-dihydrobenzopyrans and analogues thereof useful as anti-inflammatory agents |
-
1991
- 1991-12-18 GB GB9126831A patent/GB2262524A/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1924685A1 (en) * | 1968-05-15 | 1969-12-04 | Ricoh Kk | Diazotype photographic printing material |
FR2393835A1 (en) * | 1977-06-10 | 1979-01-05 | Anvar | POLYPHENYLENE OXIDE FILMS CONTAINING REAGENT GROUPS AND THEIR PREPARATION BY ELECTROCHEMICAL METHODS |
JPS5865775A (en) * | 1981-10-15 | 1983-04-19 | Terumo Corp | Ion contact preventing membrane |
EP0081782A1 (en) * | 1981-12-14 | 1983-06-22 | Merck & Co. Inc. | Hydroxybenzylamino-aryl compounds, process for preparing and pharmaceutical compositions containing the same |
US4578390A (en) * | 1981-12-14 | 1986-03-25 | Merck & Co., Inc. | Hydroxybenzylamino derivatives as anti-inflammatory agents |
EP0122321A1 (en) * | 1983-04-13 | 1984-10-24 | Merck & Co. Inc. | Hydroxybenzylamino derivatives as anti-inflammatory agents |
EP0150291A1 (en) * | 1983-11-21 | 1985-08-07 | Merck & Co. Inc. | Substituted 5-hydroxy-2,3-dihydrobenzofurans and 6-hydroxy-2,3-dihydrobenzopyrans and analogues thereof useful as anti-inflammatory agents |
Non-Patent Citations (5)
Title |
---|
Chemical Abstracts 67 (25): 116735f and Uch. Zap. Azerb. GosUniv., Ser. Khim. Nauk, No.1, 11-14 * |
Chemical Abstracts 86 (9): 54830q and Zh. Org. Khim, 12 (9),1945-55 * |
Inorg. Chim. Acta,68, 41-3 * |
J. Chem Soc., Perkin Trans. 1, (12), 3041 -7 * |
J. Med. Chem.,33 (3), 908-18 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552066B1 (en) | 1995-09-11 | 2003-04-22 | Thomas R. Sharpe | Protein tyrosine kinase inhibitors for treating osteoarthritis |
Also Published As
Publication number | Publication date |
---|---|
GB9126831D0 (en) | 1992-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5155110A (en) | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition | |
KR100674160B1 (en) | Drugs for the treatment of malignant tumours | |
SI9620103A (en) | Pyrrolopyrimidines and processes for the preparation thereof | |
JPH0555506B2 (en) | ||
US3634453A (en) | Oxindole carboxamides | |
MX2007013225A (en) | Imidazo [1, 2-a] pyridine derivatives useful as peptide deformylase (pdf) inhibitors. | |
CZ292391B6 (en) | Benzamide derivative substituted with heterocyclic groups and use thereof | |
JP2012502964A (en) | Aryl-phenyl-sulfonamido-cycloalkyl compounds and uses thereof | |
Traxler et al. | Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase | |
JPH10510536A (en) | 2-Substituted 1,2,5-thiadiazolidine-3-one 1,1-dioxides and compositions thereof | |
FI67686C (en) | PROCEDURE FOR THE FRAMEWORK OF THERAPEUTIC ANIMAL PRODUCTS | |
CA2116621C (en) | Novel anticancer agents | |
KR960702442A (en) | Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors as tyrosine kinase inhibitors | |
EP0172608B1 (en) | Novel triazine derivative, process for preparing same and pharmaceutical preparations containing same | |
FI93108C (en) | Process for the preparation of 2-benzothiazoline derivatives useful as a drug | |
EP3388419A1 (en) | Gli1 inhibitors and uses thereof | |
JPH05507072A (en) | Heterocyclic ethenediyl compounds that inhibit EGF receptor tyrosine kinase | |
CA2423628A1 (en) | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them | |
GB2262524A (en) | Pharmaceutically active 2-hydroxy-benzylamines | |
US4057556A (en) | Troponyl-oxamic acid derivatives | |
JPH01501477A (en) | antifolate | |
FI57589C (en) | REFERENCE TO A FRAME TRACTOR 6-SUBSTITUTE 3-CARBETOXYHYDRAZINOPYRIDAZINER | |
US4792570A (en) | 3- and 4-biphenyloxyaminoalkanes and related compounds as anti-inflammatory and analgetic agents | |
US3966956A (en) | [1-(P-Chlorobenzoyl)-5-methoxy-2-methyl-3-indole]acetoxyacetic acid and salts in treating inflammation | |
EP0660821B1 (en) | Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |